UNSPSC 51182054: Nandrolone benzoate

This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C25H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1665A8I95W, chemically known as estr-4-en-3-one, 17-(benzoyloxy)-, (17.beta.)-, but more generally known as nandrolone benzoate, which bears US NIH Compound Identifier 227796. European Medicines Agency schedules nandrolone benzoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09148MIG.

Most nations, for tariff purposes, schedule nandrolone benzoate under HS 29372900. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)C4CCCCC4)CCC5=CC(=O)CC[C@H]35.

UNSPSC 51182054 Nandrolone benzoate is a Commodity code covering a specific anabolic steroid pharmaceutical used in state and local procurement primarily through cooperative purchasing vehicles. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration's Office of State Procurement solicited nandrolone benzoate as part of a broader generic multi-source pharmaceuticals and over-the-counter products RFP, indicating that this code captures individual pharmaceutical line items bought through statewide and regional health-system contracts rather than as standalone commodity acquisitions. State and local governments purchase under this code chiefly through health departments, corrections agencies, and hospital systems via cooperative purchasing agreements. The scope includes supply of FDA-compliant generic pharmaceuticals with specified National Drug Codes, packaging configurations, manufacturing locations, and pricing submitted through authorized wholesaler networks (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, and Morris & Dickson Co., LLC), with vendors required to maintain cGMP certification and Drug Supply Chain Security Act compliance.

The MMCAP RFP issued January 20, 2026, with proposals due March 26, 2026, spans Minnesota and participating states including Oregon. The procurement evaluates vendors on price competitiveness (75 percent weight), fixed pricing stability (10 percent), EDI capability (5 percent), compliance with data format and administrative fee requirements (10 percent combined), with awarded vendors effective July 1, 2026, for an initial two-year term and optional extensions. Vendors must maintain commercial general liability insurance of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million, and accept a 3 percent administrative fee on all contract purchases. No specific dollar value is disclosed in the solicitation; specific award structures will be determined by MMCAP's therapeutic considerations, product availability, patient safety priorities, and member-specific needs across participating jurisdictions.